Drug Profile
Pralsetinib - Blueprint Medicines
Alternative Names: BLU-667; CS 3009; GAVRETO; Gavreto; Pratinib; Pujihua; RG 6396Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Blueprint Medicines
- Developer Blueprint Medicines; CStone Pharmaceuticals; Roche
- Class Amides; Amines; Antineoplastics; Cyclohexanes; Ethers; Fluorinated hydrocarbons; Pyrazoles; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Proto oncogene protein c ret inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer; Thyroid cancer
- Phase II Solid tumours
Most Recent Events
- 22 Feb 2024 Blueprint terminates its licence for GAVRETO
- 22 Feb 2024 Rigel Pharmaceuticals entered into a definative agreement with Blueprint Medicines to acquired the US rights of GAVRETO® (pralsetinib) from Blueprint Medicines
- 04 Jan 2024 Roche withdraws a phase III trial in Thyroid cancer (First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In adults, In adolescents, In the elderly) in Spain, Portugal, France, Italy, Netherlands, Greece, Germany, Poland, Denmark, Sweden, Bulgaria (PO) prior to enrolment due to several logistical challenges during start-up (NCT04760288) (EudraCT2020-005269-15)